Kidney - CML - Chronic Myeloid Leukemia
''Treatment of chronic myeloid leukemia (CML) with various tyrosine kinase inhibitors (TKIs) can induce changes in glomerular filtration rate (GFR) over time and have other kidney-related effects, according to a new study. Imatinib and dasatinib were associated with a decrease in GFR, while nilotinib was associated with an increase. ''
Extract of " TKIs Have Kidney Effects in Long-Term CML Treatment "
ARTICLES
Retrospective Study Reports Tyrosine Kinase Inhibitor Used in CML Associated With Nephrotoxicity
September 19, 2023, The ASCO Post
A Case of Long-Term Dasatinib-Induced Proteinuria and Glomerular Injury
May 9, 2020, PubMed
Successful Treatment of Chronic Myeloid Leukemia With Dasatinib After Kidney Transplantation: A Case Report
March 2020, Science Direct
Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors
July 2019, PubMed
What Are the Stages of Chronic Kidney Disease (CKD)?
May 28, 2018, HealthnFitness
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias
June 2017, Clinical Lymphoma, Myeloma and leukemia
Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia
March 2016, Science Direct
Tyrosine kinase inhibitors seem safe in CML with CKD
August 1, 2015, Medical Xpress
TKIs Have Kidney Effects in Long-Term CML Treatment
July 31, 2015, Cancer Network
Dasatinib-induced nephrotic-range proteinuria
2013, PubMed
Bilateral renal artery stenosis in a patient with chronic myeloid leukemia treated with nilotinib
September 2012, Science Direct
Chronic myeloid leukemia within a year of kidney transplant with elevated alkaline phosphatase correlated with imatinib therapy
October 2011, PublMed
Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease
November 13, 2010, JASN
Acute renal failure under dasatinib therapy
January 2010, PubMed
Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib
February 2008, Haematologica
Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Prostate Cancer
November 15, 2005, The Annals of Pharmacotherapy
Retrospective Study Reports Tyrosine Kinase Inhibitor Used in CML Associated With Nephrotoxicity
September 19, 2023, The ASCO Post
A Case of Long-Term Dasatinib-Induced Proteinuria and Glomerular Injury
May 9, 2020, PubMed
Successful Treatment of Chronic Myeloid Leukemia With Dasatinib After Kidney Transplantation: A Case Report
March 2020, Science Direct
Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors
July 2019, PubMed
What Are the Stages of Chronic Kidney Disease (CKD)?
May 28, 2018, HealthnFitness
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias
June 2017, Clinical Lymphoma, Myeloma and leukemia
Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia
March 2016, Science Direct
Tyrosine kinase inhibitors seem safe in CML with CKD
August 1, 2015, Medical Xpress
TKIs Have Kidney Effects in Long-Term CML Treatment
July 31, 2015, Cancer Network
Dasatinib-induced nephrotic-range proteinuria
2013, PubMed
Bilateral renal artery stenosis in a patient with chronic myeloid leukemia treated with nilotinib
September 2012, Science Direct
Chronic myeloid leukemia within a year of kidney transplant with elevated alkaline phosphatase correlated with imatinib therapy
October 2011, PublMed
Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease
November 13, 2010, JASN
Acute renal failure under dasatinib therapy
January 2010, PubMed
Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib
February 2008, Haematologica
Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Prostate Cancer
November 15, 2005, The Annals of Pharmacotherapy
